Skip to content

Clinical trials

Phase 2 Carcinoma, Hepatocellular trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Carcinoma, Hepatocellular Phase: Phase 2 Clear all

801 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20006
20016
200211
20035
200413
200513
200620
200726
200821
200927
201017
201124
201220
201314
201421
201517
201622
201725
201833
201942
202044
202166
202252
202356
202457
202567
202654

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed268
Unknown status165
Recruiting143
Terminated83
Not yet recruiting57
Withdrawn42
Active, not recruiting40
Suspended2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Sun Yat-sen University47
National Cancer Institute (NCI)38
Tianjin Medical University Cancer Institute and Hospital21
Fudan University16
Shanghai Zhongshan Hospital16
Second Affiliated Hospital of Guangzhou Medical University14
M.D. Anderson Cancer Center11
Seoul National University Hospital11
Asan Medical Center9
Bayer9

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Carcinoma, Hepatocellular801
Liver Neoplasms131
Bile Duct Neoplasms22
Gallbladder Neoplasms22
Neoplasms22
Cholangiocarcinoma21
Stomach Neoplasms19
Carcinoma, Non-Small-Cell Lung18
Colorectal Neoplasms18
Melanoma17

Trials

Showing 26 to 50 of 801. Each trial links to its page on Pharma Observatory.

701 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.